Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up
Four-year follow up data are now available from the CheckMate [...]
Survival outcomes for patients on ipilimumab plus nivolumab combination therapy
Further results from the ongoing CheckMate 214 phase III study [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer
The combination of nivolumab with ipilimumab has been proven to [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial
Results from the TITAN-RCC clinical trial to assess tailored immunotherapy [...]
Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases
An interim analysis of study Checkmate 920 has shown that [...]
